MXPA03006229A - Formulacion de esmolol. - Google Patents
Formulacion de esmolol.Info
- Publication number
- MXPA03006229A MXPA03006229A MXPA03006229A MXPA03006229A MXPA03006229A MX PA03006229 A MXPA03006229 A MX PA03006229A MX PA03006229 A MXPA03006229 A MX PA03006229A MX PA03006229 A MXPA03006229 A MX PA03006229A MX PA03006229 A MXPA03006229 A MX PA03006229A
- Authority
- MX
- Mexico
- Prior art keywords
- esmolol
- hydrochloride
- esmolol formulation
- formulation
- isopropylamino
- Prior art date
Links
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 title 1
- 229960003745 esmolol Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- VZTMYLWJKCAXMZ-UHFFFAOYSA-N 2-[(2-chloroquinazolin-4-yl)amino]ethanol Chemical compound C1=CC=C2C(NCCO)=NC(Cl)=NC2=C1 VZTMYLWJKCAXMZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001015 esmolol hydrochloride Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- GXLJZLBKWSJXFP-UHFFFAOYSA-N phenyl propanoate;hydrochloride Chemical compound Cl.CCC(=O)OC1=CC=CC=C1 GXLJZLBKWSJXFP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fats And Perfumes (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Se describe una composicion farmaceutica esteril, acuosa adecuada para administracion parenteral para el tratamiento de condiciones cardiacas, que comprende hidrocloruro de metil-3-[4-(2- hidroxi-3-isopropilamino) propoxi] fenilpropionato (hidrocloruro de esmolol), un agente amortiguador y un agente de ajuste osmotico, asi como tambien un metodo para su fabricacion.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/759,547 US6310094B1 (en) | 2001-01-12 | 2001-01-12 | Ready-to-use esmolol solution |
| US10/016,260 US6528540B2 (en) | 2001-01-12 | 2001-10-30 | Esmolol formulation |
| PCT/US2002/000329 WO2002076446A1 (en) | 2001-01-12 | 2002-01-02 | Esmolol formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03006229A true MXPA03006229A (es) | 2004-05-24 |
Family
ID=26688377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03006229A MXPA03006229A (es) | 2001-01-12 | 2002-01-02 | Formulacion de esmolol. |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1368019B2 (es) |
| JP (1) | JP2004519506A (es) |
| CN (1) | CN1298320C (es) |
| AT (1) | ATE341319T1 (es) |
| AU (1) | AU2002309475B2 (es) |
| BR (1) | BR0203517A (es) |
| CA (1) | CA2410446C (es) |
| CZ (1) | CZ304290B6 (es) |
| DE (1) | DE60215129T3 (es) |
| DK (1) | DK1368019T4 (es) |
| ES (1) | ES2272720T5 (es) |
| HU (1) | HUP0204520A3 (es) |
| IL (1) | IL151359A (es) |
| MX (1) | MXPA03006229A (es) |
| PL (1) | PL216192B1 (es) |
| RU (1) | RU2286774C2 (es) |
| SI (1) | SI1368019T2 (es) |
| SK (1) | SK288113B6 (es) |
| TR (1) | TR200202557T1 (es) |
| TW (1) | TWI277414B (es) |
| WO (1) | WO2002076446A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| EP1417962A1 (de) | 2002-11-06 | 2004-05-12 | AOP Orphan Pharmaceuticals AG | Verfahren zur Herstellung eines Arzneimittels enthaltend Esmolol |
| WO2005035000A1 (en) * | 2003-10-08 | 2005-04-21 | Mallinckrodt Inc. | Methylphenidate solution and associated methods of administration and production |
| CN1303987C (zh) * | 2004-11-19 | 2007-03-14 | 陈庆财 | 注射用盐酸艾司洛尔冻干粉针剂及其制备方法 |
| US20080293814A1 (en) * | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| AU2014203121B2 (en) * | 2007-05-22 | 2016-04-21 | Baxter Healthcare Sa | Concentrate esmolol |
| US8426467B2 (en) * | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
| US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
| ES2397126T3 (es) | 2007-12-21 | 2013-03-04 | Aop Orphan Pharmaceuticals Ag | Composición farmacéutica para la administración parenteral de un antagonista del receptor beta-adrenérgico de acción ultrarrápida |
| CN102548538B (zh) | 2009-09-22 | 2014-03-12 | V生命科学技术有限公司 | 治疗糖尿病足溃疡的局部制剂 |
| ES2363964B1 (es) | 2009-11-20 | 2012-08-22 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados. |
| US8686036B2 (en) | 2011-01-27 | 2014-04-01 | Baxter International Inc. | Methods of controlling heart rate while minimizing and/or controlling hypotension |
| WO2012103305A1 (en) * | 2011-01-27 | 2012-08-02 | Baxter International Inc. | Use of (s) - esmolol for controlling venous irritation associated with the treatment of a cardiac disorder |
| PT2846776T (pt) | 2012-05-10 | 2020-05-28 | Aop Orphan Pharmaceuticals Ag | Formulação parenteral de esmolol |
| US8835505B1 (en) | 2013-03-15 | 2014-09-16 | Welgrace Research Group | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
| CN104473869A (zh) * | 2014-11-20 | 2015-04-01 | 北京京科泰来科技有限公司 | 一种艾司洛尔脂肪乳及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0179808B1 (en) * | 1984-04-09 | 1991-10-30 | The Du Pont Merck Pharmaceutical Company | Pharmaceutical composition suitable for treatment or prophylaxis of cardiac disorders |
| US4857552A (en) * | 1988-06-08 | 1989-08-15 | E. I. Du Pont De Nemours And Co. | Stable pharmaceutical composition |
| CN1074763C (zh) * | 1997-11-13 | 2001-11-14 | 山东省医药工业研究所 | 艾司洛尔盐酸盐的制备方法 |
-
2001
- 2001-12-14 TW TW090131012A patent/TWI277414B/zh not_active IP Right Cessation
-
2002
- 2002-01-02 CN CNB028000676A patent/CN1298320C/zh not_active Expired - Lifetime
- 2002-01-02 ES ES02736473T patent/ES2272720T5/es not_active Expired - Lifetime
- 2002-01-02 CZ CZ2002-3825A patent/CZ304290B6/cs not_active IP Right Cessation
- 2002-01-02 HU HU0204520A patent/HUP0204520A3/hu not_active Application Discontinuation
- 2002-01-02 EP EP02736473A patent/EP1368019B2/en not_active Expired - Lifetime
- 2002-01-02 IL IL151359A patent/IL151359A/en active IP Right Grant
- 2002-01-02 RU RU2002132189/15A patent/RU2286774C2/ru active
- 2002-01-02 JP JP2002574961A patent/JP2004519506A/ja not_active Withdrawn
- 2002-01-02 WO PCT/US2002/000329 patent/WO2002076446A1/en not_active Ceased
- 2002-01-02 TR TR2002/02557T patent/TR200202557T1/xx unknown
- 2002-01-02 MX MXPA03006229A patent/MXPA03006229A/es active IP Right Grant
- 2002-01-02 DE DE60215129T patent/DE60215129T3/de not_active Expired - Lifetime
- 2002-01-02 DK DK02736473.6T patent/DK1368019T4/da active
- 2002-01-02 CA CA002410446A patent/CA2410446C/en not_active Expired - Lifetime
- 2002-01-02 BR BR0203517-0A patent/BR0203517A/pt not_active Application Discontinuation
- 2002-01-02 PL PL357387A patent/PL216192B1/pl unknown
- 2002-01-02 AT AT02736473T patent/ATE341319T1/de active
- 2002-01-02 AU AU2002309475A patent/AU2002309475B2/en not_active Expired
- 2002-01-02 SK SK1278-2002A patent/SK288113B6/sk not_active IP Right Cessation
- 2002-01-02 SI SI200230444T patent/SI1368019T2/sl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL151359A (en) | Esmolol formulation | |
| EP1738756A3 (en) | Esmolol formulation | |
| AU2003225617A1 (en) | Thiadiazolylpiperazine derivatives useful for treating or preventing pain | |
| ZA992951B (en) | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders. | |
| PL369108A1 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| MXPA04004842A (es) | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. | |
| MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
| IL161154A0 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| JO2282B1 (en) | Oxazole derivatives | |
| WO2004030611A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
| YU75903A (sh) | Tiohidantoini i njihovo korišćenje u lečenju dijabetisa | |
| DE602004011966D1 (en) | Heterocyclylverbindungen | |
| NO20050018L (no) | Lasofoxifentabletter og belegg | |
| BR0308133A (pt) | Forma polimórfica cristalina de cloridrato de irinotecan | |
| GB0109122D0 (en) | Novel compounds | |
| MX344556B (es) | Agonista de subtipo de receptor 5-ht1a. | |
| SE0102440D0 (sv) | New compound | |
| AU2001290480A1 (en) | Cyclized benzamide neurokinin antagonists for use in therapy | |
| CA2438509A1 (en) | Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria | |
| MXPA05008711A (es) | Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico. | |
| MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
| EP1411956B8 (en) | Use of oversulfated polysaccharides as inhibitors of hiv | |
| PL365258A1 (en) | Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions | |
| SE0002354D0 (sv) | New formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |